Cargando…

Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies

BACKGROUND: To assess the measurement properties of the Benign Prostatic Hyperplasia Impact Index (BII) for use in men with Lower Urinary Tract Symptoms (LUTS) secondary to Benign Prostatic Hyperplasia (BPH) treated with tadalafil. METHODS: Data from a dose-titration (Study 1) and a dose-finding pla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angalakuditi, Mallik, Seifert, Rita F, Hayes, Risa P, O'Leary, Michael P, Viktrup, Lars
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998470/ https://www.ncbi.nlm.nih.gov/pubmed/21073697 http://dx.doi.org/10.1186/1477-7525-8-131

Ejemplares similares

Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia
por: Viktrup, Lars, et al.
Publicado: (2012)

The Efficacy and Safety of Tadalafil 5 mg Once Daily in Korean Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: An Integrated Analysis
por: Lee, Sung Won, et al.
Publicado: (2014)

Meta-Analysis of Efficacy and Safety of Tadalafil Plus Tamsulosin Compared with Tadalafil Alone in Treating Men with Benign Prostatic Hyperplasia and Erectile Dysfunction
por: Zhou, Zhongbao, et al.
Publicado: (2019)

Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus
por: Elkelany, Osama O, et al.
Publicado: (2015)

The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction
por: Gacci, Mauro, et al.
Publicado: (2013)

Management options for the treatment of benign prostatic hyperplasia with or without erectile dysfunction: a focus on tadalafil and patient considerations
por: Alsaikhan, Bader, et al.
Publicado: (2014)

Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia
por: Tanaka, Tomoaki, et al.
Publicado: (2018)

Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride
por: Kosilov, Kirill V., et al.
Publicado: (2020)

Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
por: Gotoh, Daisuke, et al.
Publicado: (2022)

Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized study
por: Pogula, Vedamurthy Reddy, et al.
Publicado: (2019)

Attenuation of Benign Prostatic Hyperplasia by Optimized Tadalafil Loaded Pumpkin Seed Oil-Based Self Nanoemulsion: In Vitro and In Vivo Evaluation
por: Alhakamy, Nabil A., et al.
Publicado: (2019)

Comparative study of tamsulosin versus tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms. A prospective randomized study
por: Ahmad, Malik Suhail, et al.
Publicado: (2022)

Benign Prostatic Hyperplasia
Publicado: (2015)

Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations
por: Lee, Lulu K, et al.
Publicado: (2016)

Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study
por: Pattanaik, Smita, et al.
Publicado: (2019)

Measurement of autophagy flux in benign prostatic hyperplasia in vitro
por: Oh, Sung-hee, et al.
Publicado: (2020)

Three-dimensional measurement and analysis of benign prostatic hyperplasia
por: Feng, Yankun, et al.
Publicado: (2021)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

Erratum: Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study
Publicado: (2019)

Simplified Chinese version of the international prostate symptom score and the benign prostatic hyperplasia impact index: cross-cultural adaptation, reliability, and validity for patients with benign prostatic hyperplasia
por: Dun, Rong-liang, et al.
Publicado: (2022)

Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil
por: Park, Hyun Jun, et al.
Publicado: (2013)

Comparative Effectiveness of Tadalafil versus Tamsulosin in Treating Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: A Meta-Analysis of Randomized Controlled Trials
por: Guo, Boda, et al.
Publicado: (2020)

Real-World Safety and Effectiveness of Tadalafil in Patients with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Japanese Post-Marketing Surveillance Study
por: Yamazaki, Hiroyoshi, et al.
Publicado: (2020)

Efficacy and Safety of 12-week Monotherapy With Once Daily 5 mg Tadalafil for Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: Evidence-based Analysis
por: Cui, Jianwei, et al.
Publicado: (2021)

Green & Sensitive pH-dependent Spectrofluorimetric Assay of Tamsulosin Hydrochloride and Tadalafil in their New Combined Formulation for Benign Prostatic Hyperplasia: Application to Spiked Human Plasma
por: Abdel Moneim, Mona M.
Publicado: (2022)

A comprehensive review of the literature on epilepsy in selected countries in emerging markets
por: Angalakuditi, Mallik, et al.
Publicado: (2011)

Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk
por: Hung, S-C, et al.
Publicado: (2013)

Clinical Significance of the Resistive Index of Prostatic Blood Flow According to Prostate Size in Benign Prostatic Hyperplasia
por: Kwon, Se Yun, et al.
Publicado: (2016)

Silodosin in the treatment of benign prostatic hyperplasia
por: Rossi, Maxime, et al.
Publicado: (2010)

Management of benign prostatic hyperplasia with silodosin
por: Yamanishi, Tomonori, et al.
Publicado: (2009)

Pathophysiology of clinical benign prostatic hyperplasia
por: Foo, Keong Tatt
Publicado: (2017)

Epidemiology of clinical benign prostatic hyperplasia
por: Lim, Kok Bin
Publicado: (2017)

Botulinum toxin and benign prostatic hyperplasia
por: Ng, Lay Guat
Publicado: (2018)

Solving the benign prostatic hyperplasia puzzle
por: Foo, Keong Tatt
Publicado: (2016)

Tissue microenvironment and benign prostatic hyperplasia
por: Wei, Xing, et al.
Publicado: (2019)

Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia
por: AbdelRazek, Mostafa, et al.
Publicado: (2022)

Causes and consequences of injuries in children in Western Australia
por: Angalakuditi, Mallik V, et al.
Publicado: (2011)

Prostatitis and benign prostatic hyperplasia: emerging infectious diseases?
por: Hennenfent, B
Publicado: (1997)

Zinc status in benign prostatic hyperplasia and prostate carcinoma
por: Wiwanitkit, Somsri, et al.
Publicado: (2012)

Linking Pre-Diabetes with Benign Prostate Hyperplasia. IGFBP-3: A Conductor of Benign Prostate Hyperplasia Development Orchestra?
por: Protopsaltis, Ioannis, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_n11gqmbmuol9ljetv0304s6p27